Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis

Recent progress in the treatment of advanced melanoma has led to improved survival affected patients. However, novel treatments also lead considerable and distinct skin toxicity. To further characterize cutaneous adverse events (AE) systemic treatments, we conducted a single-center retrospective study biopsy-proven over period 10 years at University Hospital Zurich, Switzerland. In 102 identified patients, 135 individual AEs developed. Immune checkpoint blockade (ICB) was causal for 81 AEs, 54 were related targeted therapies (TT). Recorded types included lichenoid, maculopapular, acneiform, urticarial, panniculitis, folliculitis, psoriasiform, granulomatous, eczematous, others. The incidence higher with TT (18.54%) than ICB (9.64%, p = 0.0029). Most low-grade, although 19.21% common terminology criteria (CTCAE) Grades 3 or 4. A large spectrum documented during melanoma, phenotypes observed, depending on classes. occurred earlier ICB, associated respective This comprehensively describes occurring single center.